Monoclonal B-cell lymphocytosis with renal involvement.

We report the case of a 70-year-old man with no relevant past medical history who presented with acute kidney injury. Kidney biopsy showed diffuse interstitial infiltration with typical chronic lymphocytic leukemia (CLL) phenotype B-cells. Subsequent studies revealed a normal lymphocyte count in the peripheral blood, and there was no evidence of lymphadenopathy or hepatosplenomegaly. Blood flow cytometry demonstrated a clonal B-cell population with a CLL phenotype. Without renal involvement, this case should be classified as monoclonal B-cell lymphocytosis. Renal function improved with steroid therapy. However, the patient developed CLL with significant lymphocytosis approximately two years later. PMID: 30588987 [PubMed - in process]
Source: Saudi Journal of Kidney Diseases and Transplantation - Category: Urology & Nephrology Authors: Tags: Saudi J Kidney Dis Transpl Source Type: research

Related Links:

Authors: Yuan T, Zhang F, Zhou X, Li Y, Zhang Y, Xu Y, Wang X Abstract Proteasome inhibitors represent a novel class of drugs that have clinical efficacy against hematological and solid cancer types, including acute myeloid leukaemia, myelodysplastic syndrome an non-small cell lung cancer. It has been demonstrated that the anti-apoptotic protein B-cell lymphoma-2-associated athanogene 3 (BAG3) is induced by proteasome inhibitors in various cancer cells and serves an important role in chemotherapy resistance. The phosphatidylinositol 3-kinase (PI3K)/RAC-α serine/threonine-protein kinase (AKT) pathway is consti...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
I read with great interest the original article by Oishi and colleagues1 and the corresponding letter to the Editor composed by Katz and colleagues. Oishi and colleagues' work is one of the most recent publications from the Toronto lung transplant laboratories and has to be interpreted as such. Having established a protocol, which can be used to safely perfuse human donor lungs ex  vivo, the research group has consequently taken the next step and applies this platform to treat and improve organs.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Thoracic: Lung Transplant: Reply to Letter to the Editor Source Type: research
A more standardized approach to the classification and reporting of glomerulonephritis will help nephrologists better evaluate, treat, and manage these patients.Nephrology Dialysis Transplantation
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Nephrology Journal Article Source Type: news
Conclusion: Clinical presentations of UN are broad and non-specific; nonetheless, it is important to detect early changes in order to avoid its progression. The earlier UN is diagnosed and treated, the more successful are the clinical outcomes.RESUMO INTRODU ÇÃO: A neuropatia periférica (NU) é um distúrbio que afeta o corpo celular, o axônio ou a mielina do motor ou neurônios sensoriais periféricos e ocorre em 60%-100% dos pacientes que são submetidos à diálise por doença renal crônica. A neuropatia urêmica é atribuí...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
Conclusion: Clinical presentations of UN are broad and non-specific; nonetheless, it is important to detect early changes in order to avoid its progression. The earlier UN is diagnosed and treated, the more successful are the clinical outcomes.RESUMO INTRODU ÇÃO: A neuropatia periférica (NU) é um distúrbio que afeta o corpo celular, o axônio ou a mielina do motor ou neurônios sensoriais periféricos e ocorre em 60%-100% dos pacientes que são submetidos à diálise por doença renal crônica. A neuropatia urêmica é atribuí...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
Conclusion: Clinical presentations of UN are broad and non-specific; nonetheless, it is important to detect early changes in order to avoid its progression. The earlier UN is diagnosed and treated, the more successful are the clinical outcomes.RESUMO INTRODU ÇÃO: A neuropatia periférica (NU) é um distúrbio que afeta o corpo celular, o axônio ou a mielina do motor ou neurônios sensoriais periféricos e ocorre em 60%-100% dos pacientes que são submetidos à diálise por doença renal crônica. A neuropatia urêmica é atribuí...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
Conclusion: Clinical presentations of UN are broad and non-specific; nonetheless, it is important to detect early changes in order to avoid its progression. The earlier UN is diagnosed and treated, the more successful are the clinical outcomes.RESUMO INTRODU ÇÃO: A neuropatia periférica (NU) é um distúrbio que afeta o corpo celular, o axônio ou a mielina do motor ou neurônios sensoriais periféricos e ocorre em 60%-100% dos pacientes que são submetidos à diálise por doença renal crônica. A neuropatia urêmica é atribuí...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
Source: Annals of Hematology - Category: Hematology Source Type: research
Conclusion: Single agent daratumumab shows promising results, yielding rapid and deep haematological responses, with an acceptable safety profile, in a frail real-life AL population. Nonetheless, close attention should be paid in the future to infection and its relation to frailty in this specific group of patients.DisclosuresHerbaux: Abbvie: Consultancy, Honoraria; Gilead Sciences, Inc.: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Facon: Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees, Sp...
Source: Blood - Category: Hematology Authors: Tags: 653. Myeloma: Therapy, excluding Transplantation Source Type: research
The objective of this review is to present a review of the pharmacokinetics, pharmacodynamics, and use of alemtuzumab in kidney transplantation. A systematic literature search was conducted using Ovid Medline, Embase, and Cochrane Central Register of controlled trials. No pharmacokinetic or dose-finding studies of alemtuzumab have been performed in kidney transplantation. Although such studies were conducted in patients with CLL and MS, these findings cannot be directly extrapolated to transplant recipients, because CLL patients have a much higher load of CD52-positive cells and, therefore, target-mediated clearance will d...
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: Acute Leukemia | Chronic Leukemia | Chronic Lymphocytic Leukemia | Kidney Transplant | Kidney Transplantation | Leukemia | Middle East Health | Saudi Arabia Health | Steroid Therapy | Study | Transplants | Urology & Nephrology